Publications by authors named "S Haman"
Article Synopsis
- Overexpression of BCL-X, an antiapoptotic protein, leads to drug resistance and disease progression in various cancers, making it an attractive target for selective inhibitors.
- Initial selective BCL-X inhibitors were effective in preclinical models but caused serious cardiovascular toxicity in higher species, prompting the development of safer alternatives using antibody-drug conjugates.
- The antibody-drug conjugate AM1-15 showed promise by inhibiting tumor growth without causing cardiovascular issues, though it did present other toxicities that were addressed in the modified AM1-AAA, which is now part of the first clinical trial for a selective BCL-X-targeting drug.
Phenotypic screening provides compounds with very limited target cellular localization data. In order to select the most appropriate target identification methods, determining if a compound acts at the cell-surface or intracellularly can be very valuable. In addition, controlling cell-permeability of targeted therapeutics such as antibody-drug conjugates (ADCs) and targeted nanoparticle formulations can reduce toxicity from extracellular release of drug in undesired tissues or direct activity in bystander cells.
View Article and Find Full Text PDFBackground Context: The halo skeletal fixator provides the most rigid type of immobilization of all the orthoses that stabilize the cervical spine. Sometimes with older patients (>70 years old), the pin penetrates the cortical and cancellous bone of the skull and enters the intracranial space, which can result in serious complications such as brain injury, infection, hematoma, and loss of cerebrospinal fluid from the subarachnoid space. Currently, there is a lack of relevant literature that examines these concerns.
View Article and Find Full Text PDF